ClinicalTrials.gg
CompletedNCT03913741innovaTV 206Updated Jun 23, 2022

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

A Phase 1/2 interventional study of tisotumab vedotin in Solid Tumor, sponsored by Genmab. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Uterine Cervical Neoplasms with a site in Japan — 15 open to participants now, 23 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Japan.

Enrollment
44th of 45
23 · median 384
Started
2019
with 2 others
Phase 1/2
9 of 49
5 open now
Registered
17th of 49
by date
Lead sponsor
2 of 49
Genmab

Among the 49 studies in Uterine Cervical Neoplasms with a site in Japan, this one is the 44th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 1/2, and was the 17th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

15 of the 49 studies in Uterine Cervical Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Uterine Cervical Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies

Read the detailed description

Part 1 of this trial will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and the safety profile of tisotumab vedotin in subjects with solid malignancies. Part 2 of this trial will enroll subjects with cervical cancer to provide further data on the safety, tolerability, PK and anti-tumor activity

03

Conditions studied

  • Solid Tumor

Keywords

  • tisotumab vedotin
  • cervical cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART 1 ONLY: Subjects with locally advanced or solid tumors, who have experienced disease progression while on standard therapy or are intolerant of, or not eligible for, standard therapy.
  • PART 2 ONLY: Subjects with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.

Patients must not have received more than 2 prior systemic treatment regimens for recurrent or metastatic cervical disease.

  • according to v1.1
  • Must be at least 20 years of age on the day of signing
  • (ECOG) performance status of 0 or 1
  • Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
  • Women of must agree to use adequate during and for 6 months after the last dose of trial treatment administration
  • A man who is sexually active with a WOCBP and has not had a vasectomy must agree to use a barrier method of birth control (Part 1 only)
  • Must provide signed informed consent before any trial-related activity is carried out.

Exclusion criteria

Exclusion Criteria (Main):

  • PART 2 ONLY: bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
  • Known past or current coagulation defects leading to an increased risk of bleeding.
  • Ongoing major bleeding.
  • Has an active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Experimental tisotumab vedotin

    Open label, single arm trial where tisotumab vedotin will be administered

    Drug: tisotumab vedotin

Interventions

  • Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial

06

What researchers measure

Primary outcomes

  1. Dose Escalation and Dose Expansion: Incidence of drug-related Adverse Events (AEs) and Serious Adverse Events (SAEs) by CTCAE v5.0 [Safety]

    Time frame: Throughout the trial - until 90 days after last dose of tisotumab vedotin

  2. Dose Escalation and Dose Expansion: Incidence of Dose Limiting Toxicities (DLTs), AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities [Tolerability]

    Time frame: Throughout the trial - until 90 days after last dose of tisotumab vedotin

  3. Dose Escalation: maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of tisotumab vedotin

    Time frame: Up to 21 days after the first dose of tisotumab vedotin (each cycle is 21 days)

  4. Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Maximum concentration (Cmax) after dosing

    Time frame: Up to approximately 42 days after initial dose of tisotumab vedotin

  5. Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-t))

    Time frame: Up to approximately 42 days after initial dose of tisotumab vedotin

  6. Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin : Rate at which the drug is removed from the body (CL)

    Time frame: Up to approximately 42 days after initial dose of tisotumab vedotin

  7. Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Elimination half-life of the drug (T½)

    Time frame: Up to approximately 42 days after initial dose of tisotumab vedotin

  8. Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Time after dosing at which the maximum drug concentration was observed (Tmax)

    Time frame: Up to approximately 42 days after initial dose of tisotumab vedotin

  9. Dose Escalation and Dose Expansion: Assess immunogenicity of tisotumab vedotin by measuring and assessing Anti-drug Antibody (ADA)

    Summarized by descriptive statistics by trial part and dose

    Time frame: Throughout and at the end of trial (up to 90 days after last dose of tisotumab vedotin)

Secondary outcomes

  1. Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Objective Response Rate (ORR) (based on RECIST 1.1)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR)

    Time frame: Up to approximately 6 months after the first dose of tisotumab vedotin

  2. Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Duration of Response (DOR) (based on RECIST 1.1)

    The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 6 months after the first dose of tisotumab vedotin

  3. Dose Escalation and Dose Expansion: Evaluate antitumor activity of tisotumab vedotin by assessing Time to Response (TTR) (based on RECIST 1.1)

    TTR for a responder is defined as the time from the start of treatment with study drug to the first objective tumor response observed.

    Time frame: Up to approximately 6 months after the first dose of tisotumab vedotin

07

Study locations

8 sites
  • National Cancer Center Hosptial East
    Kashiwa-shi, Chiba-Ken 277-8577, Japan
  • NHO Shikoku Cancer Center
    Matsuyama-Shi, Ehime-Ken 791-0280, Japan
  • NHO Hokkaido Cancer Center
    Sapporo-shi, Hokkaido 003-0804, Japan
  • Kanagawa Cancer Center
    Yokohama-shi, Kanagawa-Ken 241-8515, Japan
  • Saitama Medical University International Medical Center
    Hidaka-shi, Saitama-Ken 350-1298, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka-Ken 411-8777, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo-To 104-0045, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo-To 160-8582, Japan
08

References and documents

Publications

  • Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, Hirashima Y, Kato H, Passey C, Buchbjerg JK, Harris JR, Andreassen CM, Nicacio L, Soumaoro I, Fujiwara K. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer Sci. 2022 Aug;113(8):2788-2797. doi: 10.1111/cas.15443. Epub 2022 Jun 15. PubMed 35633184 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Aug 2020, 17 months.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's 17 months is below that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 12, 2019
StartActual
Feb 27, 2019
Primary completionActual
Aug 14, 2020
CompletionActual
Oct 30, 2021
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03913741
Lead sponsor
Genmab
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Apr 12, 2019
Start date
Feb 27, 2019
Primary completion
Aug 14, 2020
Completion
Oct 30, 2021
Last update
Jun 23, 2022

Study contacts

Keiichi Fujiwara, Professor
principal investigator · Saitama Medical University International Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion